MedPage Today on MSN
Monoclonal Antibody Prevented Relapse in Adult-Onset Nephrotic Syndrome
Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...
News Medical on MSN
Rituximab Prevents Relapse in Adult-Onset Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome: JAMA
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...
Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically ...
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete ...
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or ...
The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...
Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints: Basel Wednesday, October 29, 2025 ...
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and yo ...
Roche (ROG: SIX) has reported positive top-line results from the Phase III INShore study of Gazyva (obinutuzumab) in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback